Stock Traders Purchase High Volume of Quantum-Si Call Options (NASDAQ:QSI)

Key Points

• Quantum-Si call-option activity surged: Investors purchased 3,845 call options, 134% above the typical volume of 1,644, signaling unusually high trading interest.
• Analyst sentiment remains mixed: Two analysts rate QSI a Buy, while others assign Hold and Sell ratings; the consensus is Hold with a $2.50 price target. HC Wainwright and Alliance Global Partners maintain Buy ratings, with HC Wainwright setting a $4.00 target.
• The stock remains highly volatile and unprofitable: QSI rose to $1.08, with a beta of 3.25 and a one-year range of $0.69 to $3.10. The company reported a quarterly loss of $0.11 per share, $0.34 million in revenue, and a negative net margin exceeding 6,000%.

Quantum-Si Incorporated (NASDAQ:QSI - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors bought 3,845 call options on the company. This represents an increase of 134% compared to the typical volume of 1,644 call options.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on QSI shares. Weiss Ratings raised shares of Quantum-Si from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 24th. HC Wainwright reissued a "buy" rating and set a $4.00 price target on shares of Quantum-Si in a research note on Tuesday. Alliance Global Partners restated a "buy" rating on shares of Quantum-Si in a report on Friday, August 14th. Finally, Wall Street Zen raised shares of Quantum-Si from a "sell" rating to a "hold" rating in a research note on Saturday, September 12th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $2.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new stake in Quantum-Si during the 1st quarter worth approximately $91,000. WINTON GROUP Ltd acquired a new position in Quantum-Si during the 2nd quarter worth approximately $67,000. Green Alpha Advisors LLC acquired a new position in shares of Quantum-Si during the 2nd quarter worth about $41,000. Hollencrest Capital Management grew its stake in Quantum-Si by 301.1% in the first quarter. Hollencrest Capital Management now owns 40,111 shares of the company's stock valued at $31,000 after purchasing an additional 30,111 shares in the last quarter. Finally, Corient Private Wealth LP bought a new stake in Quantum-Si during the second quarter worth $34,000. 39.90% of the stock is owned by institutional investors and hedge funds.

Quantum-Si Stock Performance

NASDAQ:QSI traded up $0.12 during trading hours on Wednesday, hitting $1.08. The stock had a trading volume of 6,143,822 shares, compared to its average volume of 4,428,813. The business's 50 day moving average is $0.77 and its 200-day moving average is $0.87. The company has a market cap of $235.52 million, a price-to-earnings ratio of -2.36 and a beta of 3.25. Quantum-Si has a one year low of $0.69 and a one year high of $3.10.

Quantum-Si (NASDAQ:QSI - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). Quantum-Si had a negative net margin of 6,138.26% and a negative return on equity of 47.12%. The company had revenue of $0.34 million for the quarter, compared to analysts' expectations of $0.30 million. On average, sell-side analysts anticipate that Quantum-Si will post -0.47 EPS for the current fiscal year.

Quantum-Si Company Profile

Quantum-Si Incorporated NASDAQ: QSI is a life sciences technology company focused on advancing proteomics, the study of proteins and their roles in biological systems. The company develops tools intended to help researchers identify and analyze proteins at the single-molecule level, supporting applications in drug discovery, translational research and precision medicine.

Its primary offering is the Platinum platform, which combines an automated instrument, proprietary sequencing technology, consumables and software for protein analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.